Compare
Indaptus Therapeutics, Inc. vs ProMIS Neurosciences Inc. vs Kala Bio, Inc. vs Can-Fite BioPharma Ltd.
| Latest fiscal year | Indaptus Therapeutics, Inc. INDP | ProMIS Neurosciences Inc. PMN | Kala Bio, Inc. KALA | Can-Fite BioPharma Ltd. CANF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $405.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | -39.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$20.85M | -$39.72M | -$26.98M | -$9.83M |
| EPS (Diluted) | -$21.58 | -$22.61 | -$3.31 | -$5.97 |
| Operating cash flow | -$14.82M | -$28.12M | -$31.99M | -$8.95M |
| Free cash flow | n/a | n/a | n/a | -$8.95M |
| Cash & equivalents | $8.51M | $6.12M | $7.56M | $5.53M |
| Total assets | $9.31M | $9.18M | $9.49M | $9.51M |
| Total liabilities | n/a | $10.44M | $2.49M | n/a |
| Shareholders' equity | $3.15M | -$1.26M | $7.00M | $5.59M |
| Return on year-end equity | -661.5% | n/a | -385.6% | -175.8% |
| Shares outstanding | 2.17M | 2.15M | 27.85M | 2.62M |
Revenue, most recent five fiscal years
| Fiscal year | Indaptus Therapeutics, Inc. | ProMIS Neurosciences Inc. | Kala Bio, Inc. | Can-Fite BioPharma Ltd. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $405.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | $674.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $743.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $3.89M Ended 2022-12-31 | $810.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $11.24M Ended 2021-12-31 | $853.0K Ended 2021-12-31 |